Fig. 1

MTT and mRNA levels in MDA-MB-231 cells after pharmacological inhibition and siRNA knockdown of EZH2 and EHMT2(G9a), individually and in combination. a Expression levels of KRT17, FBX032, JMJD3, EZH2, SPINK1 and EHMT2 were measured by qRT-PCR in the MDA-MB-231 cell line 48 h after transfection with siRNAs targeting EZH2 and EHMT2, both individually and in combination. All measurements were normalised to the fold-change (relative to GAPDH) in the mock transfection control. Error bars represent the mean ± SD of experiment performed in technical triplicate. b Expression levels of KRT17, FBX032, JMJD3 and SPINK1 were measured by qRT-PCR in the MDA-MB-231 cell line treated for 48 h with GSK343, UNC0638, and UNC0638 (at 7.5 μM) with increasing doses of GSK343. Each group has been compared to the untreated sample following normalisation to GAPDH. Error bars represent the mean ± SD of experiment performed in technical triplicate. c MTT assay for cell viability of MDA-MB-231 cells after treatment. MDA-MB-231 cells were seeded in 96 well plates. After 24 h, increasing doses of GSK343, UNC0638 or combination treatments (1, 2.5, 5, 7.5, 10 and 15 μM) were added to cells. Control was media with 0.5 % DMSO. Cell viability was measured by MTT assay after a 48-h treatment and a 24-h proliferation period. Error bars represent the mean ± SEM of five independent repeats